Technology Platform | ProteoThera

Technology platform

Matrix Binding Technology Platform

ProteoThera has developed a tissue matrix binding (MB) protein fusion targeting technology to re-engineer previously validated therapies.

MB platform technology for proteins involves fusion with a proprietary matrix binding sequence based on a 21 amino acid peptide derived from a naturally occurring protein.

The result is site-specific extended retention in the extracellular matrix of charged, proteoglycan-rich tissues — while keeping biologic activity.

Diagram: tagged protein binds proteoglycans; untagged leaves — Tagged protein enters the tissue matrix and binds proteoglycans and cells; untagged protein exits to systemic circulation.

Matrix binding fusion for proteins

MB platform technology for proteins involves fusion with a proprietary matrix binding sequence based on a 21 amino acid peptide derived from a naturally occurring protein.

Site-specific retention

MB targeting enables site-specific extended retention in the extracellular matrix (ECM) of naturally occurring charged proteoglycan-rich tissues, while maintaining biologic activity.

Widely adaptable

The MB technology platform is widely adaptable for use with proteins, peptides or other small molecules. ProteoThera’s proprietary analog of an endogenous heparin-binding domain peptide has been optimized to allow for both extended retention and biologic activity during the therapeutic window.

Creating new pharmacokinetic profiles

The MB technology can generate new pharmacokinetic profiles for therapies, transforming systemically delivered drugs into locally delivered drugs.

Schematic of a matrix-binding fusion protein — MB fusion protein schematic from the company’s site.

Adaptability

Proteins, peptides, small molecules

ProteoThera’s proprietary analog of an endogenous heparin-binding domain peptide has been optimised to allow both extended retention and biologic activity during the therapeutic window.

That means the same targeting idea can be applied beyond proteins — to peptides and other small molecules.

The evidence behind the platform

At the ACR/ARHP Annual Meeting in 2016, the team presented a matrix-binding IL1RA fusion with IC50 of 152 pM ± 26 pM, against 175 pM ± 23 pM for anakinra — no loss of potency — and retention in cartilage after wash-out.

Pancoast J, Lee RT, Patwari P. ACR/ARHP Annual Meeting 2016, abstract 3076.